US regulators to weigh controversial peptides backed by RFK Jr

What the report says

Al Jazeera reports that a US Food and Drug Administration advisory panel is set to consider whether seven peptide compounds should be allowed to be prepared by licensed compounding pharmacies for patients with prescriptions. The Pharmacy Compounding Advisory Committee is scheduled to meet Thursday and Friday, as demand grows for peptides marketed for uses such as sleep, weight loss, muscle growth, wound healing, inflammation, migraines, chronic pain and opioid withdrawal.

Peptides are short amino-acid chains that exist naturally in the body and can influence biological functions. Some peptide-based medicines, including GLP-1 drugs such as Ozempic and Wegovy, are approved and widely used, but Al Jazeera notes that the compounds under review — including BPC-157, TB-500 and KPV — are a separate category promoted for a wide range of wellness and medical claims. FDA scientists have questioned whether there is enough evidence that the seven products are safe or effective, citing limited human trial data and concerns about product quality, stability and consistency.

The review comes amid broader public attention driven by wellness clinics, influencers, online forums and endorsements from US Health and Human Services Secretary Robert F Kennedy Jr, who has said he used peptides with positive results and argued restrictions can push consumers toward unregulated sources. Industry groups say allowing licensed pharmacy compounding could improve oversight and quality control.

Al Jazeera, citing AP, also reports controversy over the advisory panel’s composition, saying half of its 14 members have links to businesses or clinics involved in peptide therapies. HHS said members underwent standard ethics vetting. The panel’s advice is not binding, but it is expected to influence the FDA’s final decision.